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Letters to the Editors www.AJOG.orgScreening tool does not select for bleeding
disorders in women with menorrhagia
TO THE EDITORS:Dr Philipp and her colleagues propose an
elegant screening tool to select women with menorrhagia for
hemostatic testing.1 They must be commended for their work
n the improvement of care for these women.
However, we have 2 major concerns with the current study.
The first is that the population does not leavemuch room for
fficient and effective screening: with a pretest probability of
ny coagulation disorder of 71%, the use of simply testing ev-
ryone is already very high. Also, the unusually high prevalence
f coagulation disorders could limit the generalizability of
ndings from this population.
The second is their interpretation of the screening tool as
seful. Given the prevalence (pretest probability) of 71%
oagulation defects in these women, a positive predictive
alue of 72% with a positive screening test does not add
dditional information. The tool seems to have simply se-
ected a random sample of their population, with the same
revalence as in the total population. By adding high PBAC
core or low serum ferritin, the size of the sample increases
ut it is still random, as illustrated by no change in the
ositive predictive value. To illustrate, if we would increase
he sample to all women, sensitivity would further increase
o 100%, with the constant predictive value of 71%. Another
ay to illustrate this is to calculate the positive likelihood
atio (LR), the factor that converts pretest probability to
osttest probability if a test is positive. The major advantage
f a LR is that it is independent of the disease prevalence in
given population, in contrast with the positive predictive
alue. A test that adds no information has a LR of 1. Tests
ith LR values between 0.5 and 2.0 are generally considered
ot useful.2 The screening tool in the Phillip study has a
positive likelihood ratio of 1.06.
To test whether the tool might perform better in a popula-
tion with a lower prevalence of coagulation defects, we applied
it to a population at our clinic (unpublished data). In this
group, platelet aggregation or coagulation defects were diag-
nosed in 29% of women. In this study, sensitivity was 67%,
specificity 24%, positive predictive valuewas 27%, and positive
LR was 0.87.
In conclusion, we cannot agree with Dr Philipp that, in its
current form, the proposed screening tool is useful in clinical
practice. f
KarinaMeijer, MD, PhD
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REPLY
We appreciate the letter to the editor by Drs Meijer, Knol, and
Veeger regarding our article.1 Because 5% of reproductive age
females present to physicians with complaints ofmenorrhagia,
universal laboratory testing is not feasible. The multiple labo-
ratory tests necessary for the diagnosis of von Willebrand dis-
ease, platelet dysfunction, and coagulation defects, prevalent in
women withmenorrhagia, are complex, expensive, not readily
available, and are not generally undertaken by gynecology
practices where most women with menorrhagia seek medical
attention. The average delay in diagnosis of bleeding disorders
from symptomonset has been estimated to be 16 years.2 There-
fore, a simple easy to administer, no cost screening tool that
would capture large numbers of women with bleeding disor-
ders and yet reduce themenorrhagia population needing diag-
nostic laboratory testingwould optimize the referral of women
and result in earlier diagnosis.
The screening tool was developed and its high sensitivity was
confirmed in aUSmultiracial populationofwomenpresenting
with unexplainedmenorrhagia.1 Although the operating char-
acteristics of the tool (ie, sensitivity and specificity) should be
inherent to the tool itself, we agree that the performance of the
tool (ie, predictive value) may vary with the population it is
evaluated in. Details of the authors’ low-riskDutch population
compared with our US multiracial menorrhagia population
would be of interest. Most importantly the screening tool was
not designed to be used in isolation or to be diagnostic for
bleeding disorders, but rather to be used to identify women for
referral to the hematologist for subsequent diagnostic hemo-
static testing in conjunction with an extensive personal and
family bleeding history.
Few screening approaches have both high sensitivity and
specificity and there is generally a trade-off between sensitivity
and specificity.3 For this screening tool, we chose high sensitiv-
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